Skip to content

Public FDA record

Z-0599-2025: Atellica CH 2-Microglobulin (B2M) - In vitro diagnostic use in the quantitative determination of 2-microg

Recall record Z-0599-2025 for Siemens Healthcare Diagnostics, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0599-2025
Company in FDA record
Siemens Healthcare Diagnostics, Inc.
FDA classification date
Dec 4, 2024
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Potential for falsely depressed auto-diluted results for samples above the measuring interval of 18.00 mg/L, up to 30.00 mg/L, when using the Atellica CH 2-Microglobulin (B2M) reagent.

Source facts

Action
Siemens issued Urgent Medical Device Correction (UMDC) ACHC25-02.A.US was issued to US affected customers by FedEx beginning on 10/28/2024 and Urgent Field Safety Notice (UFSN) ACHC25-02.A.OUS. Letter states reason for recall, health risk and action to take: Please review this letter with your Medical Director to determine the appropriate course of action, including for any previously generated results, if applicable. " Manually dilute patient samples that are > 18.00 mg/L: 1. Navigate to the CH Test Definition screen. 2. Under Measuring Interval, uncheck Repeat when Outside Measuring Interval. 3. For samples that generate test results > 18.00 mg/L, prepare a 1:2 manual dilution with saline solution (0.9% unbuffered Isotonic saline). 4. From the Create Patient Order screen, order the sample and enter 2 in the manual dilution field on the left of the screen. Note: The system will apply the 1:2 dilution factor and calculate the final result. 5. Process the manually diluted sample. "Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days. "Please retain this letter with your laboratory records and forward this letter to those who may have received this product. Resolution The Atellica CH B2M assay IFU will be updated with the above steps to support manual 1:2 dilution only with saline for samples > 18.00 mg/L. Please see Appendix, Table 2, for data using these revised instructions. Contact your Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative.
Initiated
2024-10-21
Root cause
Under Investigation by firm
Distribution
Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Czech Republic, Denmark, Ecuador, Egypt, Finland, France, Germany, Greece, Hungary, India, Iran, Israel, Italy, Ivory Coast, Japan, Jordan, Kuwait, Mexico, Morocco, Oman, P.R. China, Pakistan, Paraguay, Poland, Portugal, Saudi Arabia, Saudi Arabia, Serbia, Slovakia, South Africa, Spain, Switzerland, Thailand, Turkey, U.A.E., Uganda, United Kingdom, Uruguay, Uzbekistan, Vietnam, Zaire.
Recall number
Z-0599-2025
Recall status
Open, Classified
CDRH record ID
210915
FDA classified
2024-12-04
Recall event number
95666

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗